We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-3.44%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.06B
AUM Growth
-$462M
(-30%)
Cap. Flow
-$154M
Cap. Flow
% of AUM
-14.49%
Top 10 Holdings %
Top 10 Hldgs %
54.06%
Holding
50
New
9
Increased
12
Reduced
4
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$58.9M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$49.9M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$38.1M |
| 4 |
Orthofix Medical
OFIX
|
+$36.2M |
| 5 |
VOLC
VOLCANO CORPORATION COM STK
VOLC
|
+$26.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$75.3M |
| 2 |
Community Health Systems
CYH
|
+$63M |
| 3 |
HCA Healthcare
HCA
|
+$50.7M |
| 4 |
Tenet Healthcare
THC
|
+$42.2M |
| 5 |
Labcorp
LH
|
+$41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.02% |
| 2 | Miscellaneous | 16.4% |
| 3 | Consumer Discretionary | 2.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceutical Industries Limited
TEVA
$45.3B
| $94.1M | 8.84% |
1,750,000
| – | – |
|
2
Viatris
VTRS
$19.2B
| $63.7M | 5.98% |
1,400,000
+400,000
| +40% | +$19.4M |
|
|
MASI
3
DELISTED
Masimo
MASI
| $57.5M | 5.4% |
2,700,000
+880,000
| +48% | +$20.1M |
|
|
GHDX
4
DELISTED
Genomic Health, Inc.
GHDX
| $56.6M | 5.32% |
2,000,000
+275,000
| +16% | +$7.67M |
|
|
5
GSK
GSK
$100B
| $55.2M | 5.18% |
+960,000
| New | +$58.9M |
|
|
VOLC
6
DELISTED
VOLCANO CORPORATION COM STK
VOLC
| $53.7M | 5.05% |
5,050,000
+1,900,000
| +60% | +$26.3M |
|
7
CONMED
CNMD
$1.41B
| $51M | 4.79% |
1,385,000
| – | – |
|
|
ESRX
8
DELISTED
Express Scripts Holding Company
ESRX
| $49.4M | 4.65% |
+700,000
| New | +$49.9M |
|
|
KERX
9
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $48.1M | 4.52% |
3,500,000
+500,000
| +17% | +$7.65M |
|
|
10
CALL
GSK
GSK
$100B
| $46M | 4.32% |
+800,000
| New | +$49M |
|
|
11
Vertex Pharmaceuticals
VRTX
$130B
| $44.9M | 4.22% |
+400,000
| New | +$38.1M |
|
|
12
Orthofix Medical
OFIX
$367M
| $37.5M | 3.52% |
1,210,164
+1,091,481
| +920% | +$36.2M |
|
|
UAM
13
DELISTED
Universal American Corp
UAM
| $33.6M | 3.16% |
4,178,259
| – | – |
|
|
ACHN
14
DELISTED
Achillion Pharmaceuticals
ACHN
| $32.4M | 3.05% |
3,250,000
-2,550,000
| -44% | -$23.7M |
|
|
ARIA
15
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $32.4M | 3.04% |
6,000,000
+1,000,000
| +20% | +$5.84M |
|
16
Quest Diagnostics
DGX
$27.2B
| $30.3M | 2.85% |
500,000
-600,000
| -55% | -$37M |
|
|
WW
17
DELISTED
WW International
WW
| $27.4M | 2.58% |
1,000,000
+150,000
| +18% | +$3.42M |
|
|
18
CALL
Teva Pharmaceutical Industries Limited
TEVA
$45.3B
| $26.9M | 2.53% |
500,000
| – | – |
|
|
AMAG
19
DELISTED
AMAG Pharmaceuticals
AMAG
| $23.9M | 2.25% |
+750,000
| New | +$16M |
|
|
SQNM
20
DELISTED
SEQUENOM INC NEW
SQNM
| $23.8M | 2.23% |
8,000,000
+1,700,000
| +27% | +$6.22M |
|
21
Novavax
NVAX
$1.54B
| $19.8M | 1.86% |
237,500
| – | – |
|
22
Bruker
BRKR
$8.88B
| $18.5M | 1.74% |
1,000,000
+500,000
| +100% | +$10.7M |
|
23
ICU Medical
ICUI
$3.94B
| $17.8M | 1.67% |
277,583
| – | – |
|
|
BRLI
24
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
| $15.3M | 1.43% |
543,724
| – | – |
|
|
WCG
25
DELISTED
Wellcare Health Plans, Inc.
WCG
| $14.2M | 1.33% |
+235,174
| New | +$15.6M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q3 2014 Portfolio in Review
As of Q3 2014, Camber Capital Management held 50 positions worth $1.06B, down 30% from $1.53B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Camber Capital Management withdrew a net $154M in Q3 2014, closing 13 positions and reducing 4 holdings. Its most notable exit was Elevance Health, an estimated $75.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 69% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
Against the trend, Camber Capital Management opened a new position in GSK worth $55.2M.
- Camber Capital Management's largest Q3 2014 buy was GSK: 960,000 shares worth $55.2M.
- Camber Capital Management added most to Orthofix Medical in Q3 2014, an estimated $36.2M increase.
- Camber Capital Management's biggest Q3 2014 reduction was Quest Diagnostics, cutting an estimated $37M.
- Camber Capital Management fully exited Elevance Health in Q3 2014, selling an estimated $75.3M.
- Camber Capital Management's ten largest holdings make up 54% of its $1.06B portfolio in Q3 2014.
- Camber Capital Management opened 9 new positions and closed 13 in Q3 2014.
- Camber Capital Management's portfolio value fell 30% quarter-over-quarter to $1.06B.
Based on Camber Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.